AMMURAVID
Start Date
Duration
Title: Factorial, multicentric, randomized clinical trial of remdesivir and immunotherapy in combination with dexamethasone for moderate COVID-19 (the AMMURAVID trial) Design: Factorial, multicentric, randomized clinical trial
Registration Number: EudraCT Number: 2020-001854-23
Primary Objective: To assess the effect of and the interaction between remdesivir and baricitinib in combination with dexamethasone on the progression to very severe respiratory failure with PaO2/FiO2 ratio <200 mmHg (ARDS-range) or mortality.
Secondary Objective(s): To assess the effects of and the interaction between remdesivir and baricitinib in combination with dexamethasone on surrogate markers of COVID-19 severity and course with particular attention towards modelling kinetics of markers of immune response associated with disease evolution.
Interested in collaboration? Contact: Diletta Pezzani mariadiletta.pezzani@univr.it
Publications: Submitted
Partners
ASST Fatebenefratelli Sacco (Coordinator),
University of Verona (Coordinator),
Luigi Sacco Hospital,
University of Tor Vergata,
University of Milan,
INMI Lazzaro Spallanzani,
Sapienza University of Rome,
Hospital of Cremona,
Ospedali Riuniti and University of the Marche,
University of Bologna,
University of Udine
ID-CARE
Evelina Tacconelli
Maria Diletta Pezzani